Danielle, Odegue Kpadraux and Solange, Kakou-Ngazoa and Renaud, Dechi Jean-Jacques and Zelica, Diallo and Mireille, Sina Kouamé and Aboubacar, Sylla and Stéphane, Tossea Koui and Venance, Kouakou and Marius, Adagba and Basile, Apia N’Chouo Kouamé and André, Touré Offianan and Mireille, Dosso (2024) Detection of Arv-Resistant Mutants in HIV-1-Infected Individuals in a Context of Systematic Switching to an Association Based on Dolutegravir in Abidjan, Côte d’Ivoire. American Journal of Molecular Biology, 14 (03). pp. 138-151. ISSN 2161-6620
ajmb2024143_31070550.pdf - Published Version
Download (1MB)
Abstract
The emergence of antiretroviral resistance mutations represents a major threat to the achievement of national and global goals for the elimination of HIV-1 infection. The global strategy in 2019 in Côte d'Ivoire is a new national policy for the management of people living with HIV with the administration of dolutegravir (DTG)-based fixed-dose combination. The aim of our study was to evaluate HIV-1 resistance to antiretrovirals (ARVs) in infected adult subjects in Côte d’Ivoire in the context of a systematic switch to a DTG-based combination. Between February 2022 and October 2023, a cross-sectional survey with random sampling was conducted in 06 services caring for people living with HIV. A total of 139 participants were included in the study. Adults with a viral load ≥ 1000 copies/mL were tested for HIV-1 ARV resistance mutations. Molecular analyses were performed using protocol of ANRS-MIE (National Agency for Research on AIDS and emerging infectious diseases). The interpretation is performed by HIVGRAD (https://www.hiv-grade.de/cms/grade/). The frequencies of HIV-1 resistance to non-nucleotide reverse transcriptase inhibitors (NNRTIs), nucleotide reverse transcriptase inhibitors (NRTIs), integrase inhibitors (IINTs) and protease inhibitors (PIs) were 82%, 73%, 19% and 11% respectively. The main mutations observed in the different classes were K103N (45%), M184V (64%), E157Q (19%) and L10V/M46I/A71V/I54V (6%) respectively. This study reveals the emergence of resistance to DTG-based fixed-dose combinations, favored by high rates of resistance to NRTIs and NNRTIs. This finding underlines the need for enhanced viral load monitoring and HIV-1 genotyping tests to guide the choice of NRTIs for combination therapy. In addition, monitoring for mutations to second-generation NRTIs is essential, given the scale-up of DTG-based regimens currently underway in Côte d’Ivoire.
Item Type: | Article |
---|---|
Subjects: | STM Repository > Biological Science |
Depositing User: | Managing Editor |
Date Deposited: | 18 Jun 2024 12:02 |
Last Modified: | 18 Jun 2024 12:02 |
URI: | http://classical.goforpromo.com/id/eprint/5270 |